Kumar, Anil <br/><br/>
Neuroprotective potential of atorvastatin and simvastatin (HMG-CoA reductase inhibitors) against 6-hydroxydopamine (6-OHDA) induced Parkinson-like symptoms.  [electronic resource] 

 -  Brain research  Aug 2012 
 - 13-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1872-6240 
<br/><br/><label>Standard No.: </label>10.1016/j.brainres.2012.06.050  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Amphetamine<br/>Analysis of Variance<br/>Animals<br/>Atorvastatin<br/>Corpus Striatum--drug effects<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Interactions<br/>Enzyme-Linked Immunosorbent Assay<br/>Glutathione--metabolism<br/>Heptanoic Acids--therapeutic use<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--therapeutic use<br/>Interleukin-6--metabolism<br/>Male<br/>Malondialdehyde--metabolism<br/>Mitochondria--drug effects<br/>Motor Activity--drug effects<br/>NADH Dehydrogenase--metabolism<br/>Nitrites--metabolism<br/>Oxidopamine--toxicity<br/>Parkinsonian Disorders--chemically induced<br/>Pyrroles--therapeutic use<br/>Rats<br/>Rats, Wistar<br/>Simvastatin--therapeutic use<br/>Tetrazolium Salts<br/>Thiazoles<br/>Tumor Necrosis Factor-alpha--metabolism